How continuous-like processes improve affordability for viral vaccines - Example of LAIV by Castillo, Jose
Engineering Conferences International
ECI Digital Archives
Integrated Continuous Biomanufacturing II Proceedings
Fall 11-4-2015
How continuous-like processes improve
affordability for viral vaccines - Example of LAIV
Jose Castillo
Univercells SA, j.castillo@univercells.com
Follow this and additional works at: http://dc.engconfintl.org/biomanufact_ii
Part of the Biomedical Engineering and Bioengineering Commons
This Conference Proceeding is brought to you for free and open access by the Proceedings at ECI Digital Archives. It has been accepted for inclusion in
Integrated Continuous Biomanufacturing II by an authorized administrator of ECI Digital Archives. For more information, please contact
franco@bepress.com.
Recommended Citation
Jose Castillo, "How continuous-like processes improve affordability for viral vaccines - Example of LAIV" in "Integrated Continuous
Biomanufacturing II", Chetan Goudar, Amgen Inc. Suzanne Farid, University College London Christopher Hwang, Genzyme-Sanofi
Karol Lacki, Novo Nordisk Eds, ECI Symposium Series, (2015). http://dc.engconfintl.org/biomanufact_ii/87
  1/1 
 
 
HOW CONTINUOUS-LIKE PROCESSES IMPROVE AFFORDABILITY FOR VIRAL VACCINES - EXAMPLE 
OF LAIV 
 
Jose Castillo 
Univercells S.A. 
j.castillo@univercells.com 
 
Designing a continuous process for a life viral vaccine could be seen useless, and challenging, as the virus 
infection will kill the cell substrate after 2-5 days of infection. 
From the technical perspective, chaining the operations of cell culture under perfusion and viral production, 
clarification and capture / concentration is an efficient option to setup a small scale continuous automated 
process to manufacture massive amounts of viral vaccines. 
We will show how beneficial it can be in terms of process development, manufacturing simplicity, capital 
expenditure and cost of production. Also, we will show how this approach can help producers of viral vaccines to 
produce at very low cost even for segmented markets for which small amounts of multiple vaccines are needed. 
 
 
